8 Results for "

CWR22Rv1

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "CWR22Rv1" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-19527
CAS No.: 13484-66-7
Synonyms: N6-Benzyladenosine-5'-phosphate
Target:  

STAT Apoptosis

Research Areas:  

Cancer

IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC50s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML) .
loading...
    loading...
Cat. No.: HY-160777
CAS No.: 1630820-51-7
Synonyms: Galeterone 3β-imidazole
Research Areas:  

Cancer

VNPP433-3β (Galeterone 3β-imidazole) is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β induces cell apoptosis. VNPP433-3β inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-121522
CAS No.: 332173-89-4
Purity:  99.20%
Target:  

Histone Demethylase

Research Areas:  

Cancer

SD-70 is an inhibitor for histone demethylase JMJD2C and exhibits antitumor efficacy. SD-70 inhibits viability of cancer cells CWR22Rv1 (9% cell survival at 10 μM), PC3 (14% cell survival at 2 μM) and DU145 (26% cell survival at 2 μM) .
loading...
    loading...
Cat. No.: HY-177694
CAS No.: 2798907-41-0
Research Areas:  

Cancer

PROTAC AR Degrader-11 is a potent androgen receptor and androgen receptor splice variant-7 PROTAC degrader. PROTAC AR Degrader-11 shows potent cytotoxicity against both CWR22RV1 cells and VCaP cells. PROTAC AR Degrader-11 can be used in prostate cancer research .
loading...
    loading...
Cat. No.: HY-160260
CAS No.: 2638507-71-6
EP300/CBP-IN-1 (compound 172) is a potent EP300/CBP inhibitor with IC50s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .
loading...
    loading...
Cat. No.: HY-160777A
CAS No.: 3026905-92-7
Synonyms: Galeterone 3β-imidazole dihydrochloride
Research Areas:  

Cancer

VNPP433-3β (Galeterone 3β-imidazole) dihydrochloride is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β dihydrochloride induces cell apoptosis. VNPP433-3β dihydrochloride inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β dihydrochloride can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-160777B
CAS No.: 3026905-91-6
Synonyms: Galeterone 3β-imidazole hydrochloride
Research Areas:  

Cancer

VNPP433-3β (Galeterone 3β-imidazole) hydrochloride is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β hydrochloride induces cell apoptosis. VNPP433-3β hydrochloride inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β hydrochloride can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-185775
Research Areas:  

Cancer

ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine is an isotype control antibody-drug conjugate for MEDI3726 (HY-185729). It carries hinge mutations including C214S in the light chain and C226V/C229V in the heavy chain, and the toxic molecule-linker conjugate is Tesirine (HY-128952). ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine can be used in the research of prostate cancer and metastatic castration-resistant prostate cancer .
loading...
    loading...